Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

3.270 -0.060 (-1.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NRX Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
$750 Million Market Projected to Reach $3.35 Billion in 2034; Mega Opportunity for Superior Preservative-Free Ketamine Drug Treating Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM)
Via Investor Brand Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Insights Ahead: NRX Pharmaceuticals's Quarterly Earnings
 
Via Benzinga
FDA Approval of Suitability Petition on Superior Preservative-Free Ketamine Drug Supports $40 Price Target in H. C. Wainright Report on Leader in $3 Billion Suicidal Depression Market: NRXP
Via Get News
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product
Via Investor Brand Network
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine
Via ACCESS Newswire
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
$40 Price Target in New H. C. Wainright Analyst Report on Leader in $3 Billion Suicidal Depression Market with Superior NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Closes Acquisition of Dura Medical
Via Investor Brand Network
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join H.C. Wainwright’s 27th Annual Global Investment Conference; CEO Fireside Chat Set for Sept. 8, 2025, 4:30 to 5 p.m. ET
Via Investor Brand Network
NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Showcases HOPE Therapeutics at Global Passion Project Event
Via Investor Brand Network
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression
Via Investor Brand Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
New to The Street T.V. Broadcasting on Bloomberg Saturday Aug 30th. The episode features TON Strategy Company (NASDAQ: TONX), Laser Photonics (NASDAQ: LASE), Sullivan & Cromwell Senior M&A Partner Frank Aquila, and Mercurity Fintech (NASDAQ: MFH)
Via ACCESS Newswire
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Expanded Access Policy for NRX-100 Following FDA Fast Track Designation
Via Investor Brand Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
NRx Pharmaceuticals' Approach To Treating Depression And Suicide Ideation Brings Modern Solution To Centuries-Old Problem
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
NRx Pharmaceuticals' Approach To Treating Depression And Suicide Ideation Brings Modern Solution To Centuries-Old Problem
Via TheNewswire.com
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Advancements on Multiple Fronts in $3 Billion Suicidal Depression Market, Highlighted by FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs and Strategic Investment
Via Investor Brand Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
From Novel Therapies To Treat Suicidal Bipolar Depression To Launching A Network Of Clinics, NRx Pharmaceuticals Is Getting Attention On Wall Street
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
From Novel Therapies To Treat Suicidal Bipolar Depression To Launching A Network Of Clinics, NRx Pharmaceuticals Is Getting Attention On Wall Street
Via TheNewswire.com
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.